Company news
Orion Oyj Class A (OMXHEX:ORNAV) news
Every Orion Oyj Class A press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Orion Group Half-Year Financial Report January–June 2026
July 17, 2026
Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026
July 3, 2026
Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission
June 23, 2026
105,950 Orion Corporation A shares converted into B shares
May 15, 2026
Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation ...
May 12, 2026
Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with...
April 23, 2026
Orion Corporation: Managers’ transactions – Satu Ahomäki
March 10, 2026
Orion Corporation: Managers’ transactions – Mikko Kemppainen
March 10, 2026
Orion Corporation: Managers’ transactions – Juhani Kankaanpää
March 10, 2026
Orion Corporation: Managers’ transactions – Liisa Hurme
March 10, 2026
Orion Corporation: Managers’ transactions – Niclas Lindstedt
March 10, 2026
Orion Corporation: Managers’ transactions – Outi Vaarala
March 10, 2026
Orion Corporation: Managers’ transactions – René Lindell
March 10, 2026
Orion Corporation: Managers’ transactions – Julia Macharey
March 10, 2026
Orion Corporation: Managers’ transactions – Hao Pan
March 10, 2026
Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026
March 10, 2026
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
March 6, 2026
Orion Group Financial Statement documents 2025 and Remuneration Report published
February 27, 2026
The Board of Directors of Orion Corporation decided on a new plan period for the Long-term Incentive program for the company’s key persons
February 12, 2026
Notice to the Annual General Meeting of Orion Corporation
February 12, 2026
Orion Group Financial Statement Release January–December 2025
February 12, 2026
62,752 Orion Corporation A shares converted into B shares
February 3, 2026
Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026
January 30, 2026
182,827 Orion Corporation A shares converted into B shares
January 16, 2026
Recommendation by the Orion Nomination Committee on the proposals to be presented to the 2026 Annual General Meeting
January 15, 2026
Orion updates time estimate for the potential related to the annual Nubeqa® net sales recorded by Orion
January 14, 2026
Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to ex...
January 14, 2026
Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangio...
January 8, 2026
Inside information: Orion to receive EUR 180 million milestone and updates full-year outlook for 2025
December 3, 2025
71,498 Orion Corporation A shares converted into B shares
November 27, 2025
Orion receives award for international growth from the President of the Republic of Finland
November 14, 2025
Orion Group Interim Report January–September 2025
October 28, 2025
49,164 Orion Corporation A shares converted into B shares
October 24, 2025
Orion and Abzena announce exclusive commercial license for Abzena’s antibody
October 23, 2025
Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025
October 14, 2025
Maxion Therapeutics Appoints Joel Edwards as Chief Business Officer
October 1, 2025
Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal
September 30, 2025
80,802 Orion Corporation A shares converted into B shares
September 19, 2025
337,000 Orion Corporation A shares converted into B shares
August 20, 2025
Navamedic ASA: National approvals of Flexilev® in OraFID® granted across all Nordic countries
August 13, 2025
Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
July 21, 2025
Orion Group Half-Year Financial Report January–June 2025
July 18, 2025
Orion Corporation’s financial reporting and Annual General Meeting in 2026
July 18, 2025
Inside information: Orion upgrades full-year outlook for 2025
July 9, 2025
Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025
July 4, 2025
141,959 Orion Corporation A shares converted into B shares
June 23, 2025
CHMP recommends third indication for darolutamide for patients with advanced prostate cancer
June 20, 2025
Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs
June 17, 2025
U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer
June 3, 2025
Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market
May 23, 2025